ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

16 links0 made here, not in the record31 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04931342A Study Evaluating theEfficacy and Safety ofBiomarker-Driven Therapiesin Patients With Persistentor Recurrent RareEpithelial Ovarian TumorsHoffmann-La RochePhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSOvarian NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSIpatasertibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCobimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAdo-Trastuzumab EmtansineEntry “Trastuzumab Emtansine”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGiredestrantIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAbemaciclibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerInavolisibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPalbociclibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerLetrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundOlaparibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedGonadotropin-Releasing Horm…Entry “Luteinizing Hormone-Releasing …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCyclophosphamideIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Ipatasertib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Ipatasertib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2IpatasertibClaude Opus 5.5TestedCurrent
Nov 2CobimetinibClaude Opus 5.5TestedCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5TestedCurrent
Nov 2AtezolizumabClaude Opus 5.5TestedCurrent
Nov 2BevacizumabClaude Opus 5.5TestedCurrent
Nov 2PaclitaxelClaude Opus 5.5TestedCurrent
Nov 2GiredestrantClaude Opus 5.5TestedCurrent
Nov 2AbemaciclibClaude Opus 5.5Background · partnerCurrent
Nov 2InavolisibClaude Opus 5.5TestedCurrent
Nov 2PalbociclibClaude Opus 5.5Background · partnerCurrent
Nov 2LetrozoleClaude Opus 5.5BackgroundCurrent
Nov 2OlaparibClaude Opus 5.5TestedCurrent
Nov 2Gonadotropin-Releasing HormoneClaude Opus 5.5TestedCurrent
Nov 2CyclophosphamideClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 14Ovarian NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18IpatasertibRule based · role ruleTestedAgrees
Nov 18CobimetinibRule based · role ruleTestedAgrees
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleTestedAgrees
Nov 18AtezolizumabRule based · role ruleTestedAgrees
Nov 18BevacizumabRule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleTestedAgrees
Nov 18GiredestrantRule based · role ruleTestedAgrees
Nov 18AbemaciclibRule based · role ruleBackgroundAgrees
Nov 18InavolisibRule based · role ruleTestedAgrees
Nov 18PalbociclibRule based · role ruleBackgroundAgrees
Nov 18LetrozoleRule based · role ruleBackgroundAgrees
Nov 18OlaparibRule based · role ruleBackgroundOverridden
Nov 18Gonadotropin-Releasing HormoneRule based · role ruleTestedAgrees
Nov 18CyclophosphamideRule based · role ruleTestedAgrees
As of nowOvarian NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.